HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minoxidil topical cream petition

This article was originally published in The Tan Sheet

Executive Summary

Law firm Baker & Hostetler asks FDA to allow an abbreviated new drug application to change the topical dosage form for private-label Rogaine, according to a petition filed Dec. 11. The petition notes that changing the dosage for the hair regrowth product from a topical solution to a cream provides better application control and reduces the risk of skin irritation to non-affected areas. It requests the dosage change for the generic versions of Rogaine (For Women) 2 percent and Rogaine Extra Strength (For Men) 5 percent. The foam delivery form of Rogaine is patented through 2019 (1"The Tan Sheet" Sept. 11, 2006, p. 5)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS135926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel